Our Powerful Technology Platform: IMT504
IMT504 is a novel oligodeoxynucleotide immunotherapy platform developed by MABT. This proprietary and innovative technology has shown robust results in numerous animal safety and efficacy models, as well as in human studies. With over $23 million invested in research, IMT504 creates a rapid, safe, and effective immune system response, making it highly promising for addressing a variety of diseases.
Key Features of IMT504:
- Development History: Over a decade of development and testing, demonstrating a strong foundation and reliability.
- Safety Profile: Extensive testing in both humans and animals has confirmed the safety and effectiveness of IMT504.
Potential Applications:
- Rabies Treatment: Developing the world’s first effective drug for treating rabies, addressing a critical unmet medical need.
- COVID-19 Vaccines: Developing next-generation vaccines using IMT504 to enhance immune response.
- Other Diseases: Potential applications in treating other infectious diseases, CNS disorders such as Alzheimer’s and Parkinson’s disease, and certain cancers.
Practical Advantages:
- Low Dose, Low Cost: IMT504 requires low doses, resulting in a low cost of goods.
- Stability and Scalability: The platform is very stable, easy to formulate, and can be rapidly and economically scaled as necessary. IMT504 is an injectable drug with no special storage requirements.
- Market Exclusivity: Our rabies treatment developed using IMT504 has received Orphan Drug Designation, providing market exclusivity, significant tax credits, and grant opportunities.
Pioneering Rabies Treatment
We are developing the world’s first effective drug for the treatment of rabies, addressing a significant unmet medical need with a disease that has a nearly 100% fatality rate once symptoms appear.
- Most lethal disease in the world
- Disease is essentially 100% fatal
- 70,000 deaths/year
- No treatment or cure for rabies
Orphan Drug Designation
Our rabies treatment has received Orphan Drug Designation, providing market exclusivity, significant tax credits, and grant opportunities, adding substantial value to our product pipeline.
- A waiver of new drug application user fees ($3.24M)
- 7 years of market exclusivity upon approval of the orphan indication
- 50% tax credit for clinical research and testing expenses
- Direct grant opportunities only available for orphan drugs
- Total Orphan Designation value ~$5M per orphan indication
We are the first and only company to have obtained orphan designation for Rabies cure
We may qualify for Priority Review Voucher (PRV), worth ~$100 Million, upon successful clinical testing.
Upon successful clinical testing, we expect to qualify for a PRV, worth approximately $100 million. This voucher can be sold to major pharmaceutical companies, providing a significant non-dilutive financial boost.
- PRVs are awarded to companies who obtain FDA approval for rare/neglected diseases like Rabies
- Most have been selling for ~$100M
- Represents an important source of future non-dilutive capital for MABT
